EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Endogenous CD155 drives metabolic reprogramming via PI3K/AKT/HIF‐1α‐glycolysis axis to mediate anti‐PD‐1 resistance in non‐small cell lung cancer

Wei-Guang Du, Xi-Yang Tang iD, Yu-Long Zhou, Run-Ze Zhang, Zhi-Bo Feng, Meng-Chao Li, Jun-Yang Pan iD, Yao Lv, Xiao-Liang Xu, Xiao-Long Yan, Nan Ma, Jin-Bo Zhao

Clinical and Translational Medicine · 2026

DOI: 10.1002/ctm2.70741 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2026. Verfasst von Wei-Guang Du und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Proto-Oncogene Proteins c-akt, Hypoxia-Inducible Factor 1, alpha Subunit. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Plan for Enhancing the Scientific Research and Innovation Capacity of Health in Shaanxi Province, Shaanxi Outstanding Youth Natural Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Anti‐PD‐1 therapy resistance remains a critical barrier in non‐small cell lung cancer (NSCLC) management, and the underlying mechanisms are incompletely defined.

Methods

We generated CD155‑knockout (KO) NSCLC cell lines using the CRISPR‑Cas9 system and performed systematic multi‑omics analyses, including single‑cell RNA‑seq, bulk RNA‑seq, proteomics, and metabolomics. The key molecular mechanisms were further validated by immunohistochemistry (IHC), western blotting, and chromatin immunoprecipitation (ChIP). Functional assays assessed cell proliferation, migration, and metabolic phenotypes, while the therapeutic efficacy was assessed in vivo using AAV9_shCD155.

Results

Single‐cell sequencing revealed aberrantly high CD155 expression in NSCLC patients with poor response to anti‐PD‐1 therapy. High CD155 expression in NSCLC tissues correlated with unfavourable prognosis. ETS1 was identified as a direct transcriptional driver of CD155. Multi‐omics analysis and functional assays demonstrated that CD155 upregulates the expression of key glycolytic proteins (GLUT1, GLUT3, LDHB) by activating the PI3K/AKT/HIF‐1α signalling axis, thereby driving glycolytic metabolism, proliferation, and migration of tumour cells. CD155 knockout significantly suppressed these malignant phenotypes. In xenograft mouse models, monotherapy with AAV9_shCD155 effectively inhibited tumour growth and postoperative recurrence. More importantly, in humanised mouse models, combining AAV9_shCD155 with pembrolizumab produced synergistic anti‐tumour effects, more significantly suppressing tumour growth and promoting immune cell infiltration into the tumour microenvironment.

Conclusion

CD155 mediates anti‐PD‐1 resistance by activating PI3K/AKT/HIF‐1α‐driven glycolytic reprogramming. Targeting CD155 combined with anti‐PD‐1 overcomes resistance, supporting a dual‐target therapeutic strategy. Key points CD155 is identified as a key driver of anti‐PD‐1 resistance in NSCLC. CD155 promotes tumour glycolysis and malignant progression via the PI3K/AKT/HIF‐1α signalling axis. AAV9_shCD155 combined with anti‐PD‐1 markedly inhibits tumour growth and promotes immune infiltration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsProto-Oncogene Proteins c-aktHypoxia-Inducible Factor 1, alpha SubunitPhosphatidylinositol 3-KinasesReceptors, VirusDrug Resistance, NeoplasmHumansMetabolic ReprogrammingAnimalsGlycolysisMiceCell Line, TumorFemale

Stichwörter der Autor:innen

AAV9_shCD155CD155NSCLCanti‐PD‐1 therapyglycolysismechanism of resistance

Substanzen

Proto-Oncogene Proteins c-aktHypoxia-Inducible Factor 1, alpha SubunitPhosphatidylinositol 3-KinasesReceptors, Viruspoliovirus receptorHIF1A protein, human

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
  • Department of Ophthalmology, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.

ORCID-Profile: Xi-Yang Tang, Jun-Yang Pan

Förderung

  • The Plan for Enhancing the Scientific Research and Innovation Capacity of Health in Shaanxi Province
  • Shaanxi Outstanding Youth Natural Science Foundation
  • National Natural Science Foundation of China
  • 2024 Tangdu Hospital High-level Talent Cultivation Program
  • 2024 Tangdu Hospital Major Clinical Technology Innovation Projects

Zitieren

APA

Du, W. G., Tang, X. Y., Zhou, Y. L., Zhang, R. Z., Feng, Z. B., Li, M. C., Pan, J. Y., Lv, Y., Xu, X. L., Yan, X. L., Ma, N., & Zhao, J. B. (2026). Endogenous CD155 drives metabolic reprogramming via PI3K/AKT/HIF‐1α‐glycolysis axis to mediate anti‐PD‐1 resistance in non‐small cell lung cancer. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70741

Vancouver

Du WG, Tang XY, Zhou YL, Zhang RZ, Feng ZB, Li MC, et al. Endogenous CD155 drives metabolic reprogramming via PI3K/AKT/HIF‐1α‐glycolysis axis to mediate anti‐PD‐1 resistance in non‐small cell lung cancer. Clinical and Translational Medicine. 2026. doi:10.1002/ctm2.70741

BibTeX
@article{Du2026,
  author = {Du, Wei-Guang and Tang, Xi-Yang and Zhou, Yu-Long and Zhang, Run-Ze and Feng, Zhi-Bo and Li, Meng-Chao and Pan, Jun-Yang and Lv, Yao and Xu, Xiao-Liang and Yan, Xiao-Long and Ma, Nan and Zhao, Jin-Bo},
  title = {Endogenous CD155 drives metabolic reprogramming via PI3K/AKT/HIF‐1α‐glycolysis axis to mediate anti‐PD‐1 resistance in non‐small cell lung cancer},
  journal = {Clinical and Translational Medicine},
  year = {2026},
  doi = {10.1002/ctm2.70741}
}
Kostenlos starten →